Funder
Institut National de la Santé et de la Recherche Médicale
Fondation de France
H2020
Horizon 2020
Reference41 articles.
1. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial;Aman;Lancet Respir. Med.,2021
2. Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19 (Clinical Trial Registration No. NCT04394416);Ashkan,2020
3. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility;Chan;Clin. Infect. Dis.,2020
4. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion;Coleman;J. Virol.,2016
5. ABL tyrosine kinases: evolution of function, regulation, and specificity;Colicelli;Sci. Signal.,2010